Limb–girdle muscular dystrophy
| Limb–girdle muscular dystrophy | |
|---|---|
| Other names | Erb's muscular dystrophy |
| Protein MYOT (also known as TTID one of the many genes whose mutations are responsible for this condition) | |
| Specialty | Neurology, neuromuscular medicine |
| Symptoms | Pelvic muscle weakness |
| Duration | Lifelong |
| Types | 32 types |
| Causes | Genetic mutations |
| Diagnostic method | Genetic testing, and possibly muscle biopsy |
| Differential diagnosis | Muscular dystrophies: Duchenne, Becker, facioscapulohumeral, Emery-Dreifuss; Pompe disease; congenital myasthenic syndrome; motor neuropathy |
| Treatment | Occupational therapy, speech therapy, and physical therapy |
| Frequency | 2.27–10 per 100,000 |
Limb–girdle muscular dystrophy (LGMD) is a genetically heterogeneous group of rare muscular dystrophies that share a set of clinical characteristics. It is characterised by progressive muscle wasting which affects predominantly hip and shoulder muscles. LGMD usually has an autosomal pattern of inheritance. It currently has no known cure or treatment.
LGMD may be triggered or worsened in genetically susceptible individuals by statins, because of their effects on HMG-CoA reductase.